Eloxx Pharmaceuticals (ELOX) Reports Q1 Loss of $0.31/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Eloxx Pharmaceuticals Reports First Quarter 2018 Financial and Operating Results and Provides Business Update
May 10, 2018 4:01 PM EDTCompany on track to initiate Phase 2 clinical trials for investigational drug ELX-02 in cystic fibrosis and cystinosis in 2018 and sufficiently funded to top line dataÂ
Formation of Scientific Advisory Board with expertise in nonsense mutations and nonsense mediated decay
Company to host webcast and conference call on Thursday, May 10, 2018 at 4:30 pm ET
WALTHAM, Mass., May 10, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (Eloxx), (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis,... More
